Anderson, et al. (1996) “Radiotherapy Studies of Cu-64-Labeled Teta-Octreotide in Tumor-Bearing Rats” Jnl. Nucl. Med., 128P. |
Bass, et al. (1998) “Identification of the Soluble in Vivo Metabolites of Indium-111-Diethylenetriaminepentaacetic Acid-D-Phe1-Octreotide” Bioconjugate Chem., 9: 192-200. |
Bernard, et al. (1997) “D-Lysine Reduction of Indium-111 Octreotide and Yttrium-90 Octreotide Renal Uptake” Jnl. Nucl. Med., 38: 1929-1933. |
Blum, et al. (1999) “The Utility of a Somatostatin-Type Receptor Binding Peptide Readiopharmaceutical (P829) in the Evaluation of Solitary Pulmonary Nodules” Chest, 115: 224-232. |
Bogden, et al. (1997) “Proliferative response of human and animal tumours to surgical wounding of normal tissues; onset duration and inhibition” British Jnl. of Cancer, 75(7) 1021-1027. |
Breemen, et al. (1998) “Somatostatin receptor scintigraphy using [ 111-In-DTPA]Rc-160 in humans: a comparison with [111In-DTPA]octreotide” Eur.J.Nucl.Med. 25: 182-186. |
De Jong, et al. (1998) “Pre-Clinical Comparison of [DTPA0]Octreotide, [DTPA0,Tyr3] Octreotide and [DOTA0,Tyr3] Octreotide as Carriers for Somatostatin Receptor-Targeted Scintigraphy and Radionuclide Therapy” Int. Jnl. Cancer, 75: 406-411. |
Hammond, et al. (1993) “Amino acid infusion blocks renal tubular uptake of an indium-labelled somatostatin analogue” British Jnl. of Cancer, 67: 1437-1439. |
Handmaker, et al. (1998) “Comparison of a Technetium Labeled SSTR Binding Peptide (P829) and F-18 FDG PET in the Evaluation of Solitary Pulmonary Nodules” Oncology Diagnosis: Non-Antibody Posters, 39(10): 315P. |
Handmaker, et al. (1998) “Comparison of a Technetium Labeled SSTR Binding Peptide (P829) and Miraluma in the Diagnosis of Breast Cancer” Oncology Diagnosis: Non-Antibody Posters, 39(10): 315P. |
Krenning, et al. (1994) “Radiotherapy with a Radiolabeled Somatostatin Analogue”, [111In-DTPA-D-Phe1]-Octreotide Annals New York Academy of Sciences, 73: 496-506. |
Lamberts, et al. (1996) “Octreotide” New England Jnl. of Med., 334(4): 246-254. |
Leimer, et al. (1998) “Response to Treatment with Yttrium 90-DOTA-Lanreotide of a Patient with Metastatic Gastrinoma” Jnl. of Nucl. Med., 39(12): 2090-2094. |
Otte, et al. (1997) DOTATOC: a powerful new tool for receptor-mediated radionuclide therapy European Jnl. of Nucl. Med., 24(7): 792-795. |
Virgolini, et al., (1998) “Indium-111-DOTA-Lanreotide: Biodistribution, Safety and Radiation Absorbed Dose in Tumor Patients” Jnl. Nucl. Med., 39(11): 1928-1936. |
Woltering, et al. (1997) “Somatostatin analogs: angiogenesis inhibitors with novel mechanisms of action” Investigational New Drugs, 15: 77-86. |
Patel, et al. (1997) “Somatostatin Receptors” TEM, 8(10): 398-405. |
Raynor, et al. (1993) “Cloned Somatostatin Receptors: Identification of Subtype-Selective Peptides and Demonstration of High Affinity Binding of Linear Peptides” Molecular Pharmacology, 43: 838-844. |
Seregni, et al. (1998) “Radionuclide imaging of neuroendocrine tumours: biological basis and diagnostic results” European Jnl. Nucl. Med., 25: 639-658. |
Stolz, et al. (1996) “Somatostatin Analogues for Somatostatin-Receptor-Mediated Radiotherapy of Cancer” Digestion, 57(suppl 1): 17-21. |
Stolz, et al. (1998) “The somatostatin receptor-targeted radiotherapeutic [90Y-DOTA-DPhe1, Tyr3]octreotide (90Y-SMT 487) eradicates experimental rat pancreatic CA 20948 tumours” European Jnl. of Nucl. Med., 25(7): 668-674. |
Virgolini, (1997) “Receptor nuclear medicine: vasointestinal peptide and somatostatin receptor scintigraphy for diagnosis and treatment of tumour patients” European Jnl. of Clinical Investigation, 27: 793-800. |